The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients

por Frary, Evan C., Gad, Dorte, Bastholt, Lars, Hess, Søren
Publicado 2016

Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized contro...

por Tolstrup, Lærke K., Pappot, Helle, Bastholt, Lars, Möller, Sören, Dieperink, Karin B.
Publicado 2022

Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy

por Tolstrup, Lærke K., Bastholt, Lars, Zwisler, Ann-Dorthe, Dieperink, Karin B., Pappot, Helle
Publicado 2019

Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients’ and Clinicians’ Experiences

por Tolstrup, Lærke K, Pappot, Helle, Bastholt, Lars, Zwisler, Ann-Dorthe, Dieperink, Karin B
Publicado 2020

Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma

por Soerensen, Anne Vest, Ellebaek, Eva, Bastholt, Lars, Schmidt, Henrik, Donia, Marco, Svane, Inge Marie
Publicado 2020

Danish translation, cultural adaption and initial psychometric evaluation of the patient feedback form

por Tolstrup, Lærke K., Pappot, Helle, Zangger, Graziella, Bastholt, Lars, Zwisler, Ann-Dorthe, Dieperink, Karin B.
Publicado 2018

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

por Kverneland, Anders H., Enevold, Christian, Donia, Marco, Bastholt, Lars, Svane, Inge Marie, Nielsen, Claus H.
Publicado 2018

The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial

por Tolstrup, Lærke K., Bastholt, Lars, Dieperink, Karin B., Möller, Sören, Zwisler, Ann-Dorthe, Pappot, Helle
Publicado 2020

Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients

por Iversen, Trine Zeeberg, Brimnes, Marie Klinge, Nikolajsen, Kirsten, Andersen, Rikke Sick, Hadrup, Sine Reker, Andersen, Mads Hald, Bastholt, Lars, Svane, Inge Marie
Publicado 2013

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial

por Kreissl, Michael C., Bastholt, Lars, Elisei, Rossella, Haddad, Robert, Hauch, Ole, Jarząb, Barbara, Robinson, Bruce, Colzani, Raffaella, Foster, Meredith, Weiss, Richard, Schlumberger, Martin
Publicado 2020

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

por Hamid, Omid, Schmidt, Henrik, Nissan, Aviram, Ridolfi, Laura, Aamdal, Steinar, Hansson, Johan, Guida, Michele, Hyams, David M, Gómez, Henry, Bastholt, Lars, Chasalow, Scott D, Berman, David
Publicado 2011

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study

por Ascierto, Paolo A., Bastholt, Lars, Ferrucci, Pier F., Hansson, Johan, Márquez Rodas, Iván, Payne, Miranda, Robert, Caroline, Thomas, Luc, Utikal, Jochen S., Wolter, Pascal, Kudlac, Amber, Tuson, Harriet, McKendrick, Jan
Publicado 2018

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma

por Bol, Kalijn Fredrike, Ellebaek, Eva, Hoejberg, Lise, Bagger, Mette Marie, Larsen, Mathilde Skaarup, Klausen, Tobias Wirenfeldt, Køhler, Ulrich Heide, Schmidt, Henrik, Bastholt, Lars, Kiilgaard, Jens Folke, Donia, Marco, Svane, Inge Marie
Publicado 2019

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A R...

por Fink, Morten, Vittrup, Anders Schwartz, Bastholt, Lars, Svane, Inge Marie, Donia, Marco, Luczak, Adam A., Ruhlmann, Christina H., Guldbrandt, Louise Mahncke, Koehler, Ulrich Heide, Winther, Mette Lerche, Ellebaek, Eva, Haslund, Charlotte Aaquist, Schmidt, Henrik
Publicado 2021

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

por Ascierto, Paolo Antonio, Del Vecchio, Michele, Mackiewicz, Andrzej, Robert, Caroline, Chiarion-Sileni, Vanna, Arance, Ana, Lebbé, Céleste, Svane, Inge Marie, McNeil, Catriona, Rutkowski, Piotr, Loquai, Carmen, Mortier, Laurent, Hamid, Omid, Bastholt, Lars, Dreno, Brigitte, Schadendorf, Dirk, Garbe, Claus, Nyakas, Marta, Grob, Jean-Jacques, Thomas, Luc, Liszkay, Gabriella, Smylie, Michael, Hoeller, Christoph, Ferraresi, Virginia, Grange, Florent, Gutzmer, Ralf, Pikiel, Joanna, Hosein, Fareeda, Simsek, Burcin, Maio, Michele
Publicado 2020